Clemens Muehlan Selected Research

Hallucinogens (Psychedelics)

1/2019

Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Clemens Muehlan Research Topics

Disease

11	Sleep Initiation and Maintenance Disorders (Insomnia) 05/2024 - 01/2019
3	Sleep Wake Disorders 10/2021 - 03/2020
2	Body Weight (Weight, Body) 01/2023 - 11/2021
2	Sleepiness 12/2020 - 01/2019
1	Ataxia (Dyssynergia) 12/2023
1	Cognitive Dysfunction 12/2023
1	Liver Cirrhosis (Hepatic Cirrhosis) 10/2021
1	Fibrosis (Cirrhosis) 10/2021
1	Fatigue 12/2020
1	Dizziness (Lightheadedness) 12/2020
1	Headache (Headaches) 12/2020
1	Breast Neoplasms (Breast Cancer) 11/2020

Drug/Important Bio-Agent (IBA)

12	daridorexantIBA 05/2024 - 01/2019
10	Orexin Receptor AntagonistsIBA 05/2024 - 03/2020
1	OrexinsIBA 12/2023
1	Alkaline PhosphataseIBA 01/2023
1	CreatinineIBA 11/2021
1	Ethanol (Ethyl Alcohol)IBA 12/2020
1	seltorexantIBA 11/2020
1	lemborexantIBA 11/2020
1	Proteins (Proteins, Gene)FDA Link 11/2020
1	suvorexantIBA 11/2020
1	Hallucinogens (Psychedelics)IBA 01/2019

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 12/2023
1	Therapeutics 12/2023